题目内容
Axicabtagene ciloleucel is indicated for the treatment of patients with primary central nervous system lymphoma.
查看答案
搜索结果不匹配？点我反馈
更多问题
Kymriah (tisagenlecleucel, Novartis) is a CD29-directed chimeric antigen receptor (CAR) T-cell immunotherapy.
Each dose of Kymriah is a customized treatment created using patient's own B-cells, a type of white blood cell known as a lymphocyte.
The safety and efficacy of Kymriah were demonstrated in one multicenter clinical trial of 63 pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The overall remission rate within three months of treatment was 43%.
The FDA approved tisagenlecleucel with a Risk Evaluation and Mitigation Strategy (REMS) program, because of the associated risk for cytokine release syndrome (CRS) and neurologic adverse events with this immunotherapy.
微信支付 
支付宝支付